Infections account for the highest number of non-relapse-related deaths after CAR T cell therapy, underscoring the necessity for clinical risk-mitigating strategies and a deeper understanding of CAR T cell-related cytopenia.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Oluwole, O. O. et al. Biol. Blood Marrow Transplant. 26, 1581–1588 (2020).
Van Oekelen, O. et al. Nat. Med. 27, 2099–2103 (2021).
Cordas dos Santos, D. M. Nat. Med. https://doi.org/10.1038/s41591-024-03084-6 (2024).
Gagelmann, N. et al. Transplant. Cell. Ther. 30, 584.e1–584.e13 (2024).
Kwon, M. et al. Haematologica 108, 110–121 (2023).
Hill, J. A. et al. Blood 131, 121–130 (2018).
Hamilton, M. P. et al. N. Engl. J. Med. 390, 2047–2060 (2024).
Ozdemirli, M. et al. N. Engl. J. Med. 390, 2074–2082 (2024).
Ghilardi, G. et al. Nat. Med. 30, 984–989 (2024).
Reimann, H. et al. Blood Adv. 7, 2066–2069 (2023).
Frigault, M. J. et al. Blood https://doi.org/10.1182/blood.2024024104 (2024).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
V.B. receives research support from BMS, Kite Pharma, Novartis, Roche and Takeda and has received consulting fees from Kite Pharma, Novartis and Roche. M.V.M. is an inventor on patents related to adoptive cell therapies, held by Massachusetts General Hospital and the University of Pennsylvania (some licensed to Novartis); holds equity in Cargo, Model T bio, Oncternal and Neximmune; serves on the Board of Directors of 2Seventy Bio; and has served as a consultant for multiple companies involved in cell therapies. M.V.M.’s interests were reviewed and are managed by Massachusetts General Hospital, and Mass General Brigham in accordance with their conflict-of-interest policies.
Rights and permissions
About this article
Cite this article
Blumenberg, V., Maus, M.V. Tracking non-relapse mortality after CAR T cell therapy. Nat Med 30, 2413–2414 (2024). https://doi.org/10.1038/s41591-024-03212-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-024-03212-2
